New studies focus on B cells in lymphoid structures within tumors.
Three recent papers in Nature could help improve cancer treatment by immune checkpoint blockade (ICB). Checkpoint inhibitors such as the antibody therapies ipilimumab, nivolumab, and pembrolizumab promote a response against cancer